<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8806785</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4226</journal-id>
<journal-id journal-id-type="nlm-ta">Glia</journal-id>
<journal-id journal-id-type="iso-abbrev">Glia</journal-id>
<journal-title-group>
<journal-title>Glia</journal-title>
</journal-title-group>
<issn pub-type="ppub">0894-1491</issn>
<issn pub-type="epub">1098-1136</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31267577</article-id>
<article-id pub-id-type="pmc">7212549</article-id>
<article-id pub-id-type="doi">10.1002/glia.23671</article-id>
<article-id pub-id-type="manuscript">NIHMS1580938</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Olsen</surname>
<given-names>Abby L.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7680-1758</contrib-id>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feany</surname>
<given-names>Mel B.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Neurology, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts</aff>
<aff id="A2"><label>2</label>Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts</aff>
<author-notes>
<corresp id="CR1"><bold>Correspondence:</bold> Mel B. Feany, Department of Pathology, Harvard Medical School, Brigham and Women’s Hospital, Harvard New Research Building, Room 630, 77 Avenue Louis Pasteur, Boston, MA 02115, USA., <email>mel_feany@hms.harvard.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>2</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>03</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>11</day>
<month>5</month>
<year>2020</year>
</pub-date>
<volume>67</volume>
<issue>10</issue>
<fpage>1933</fpage>
<lpage>1957</lpage>
<!--elocation-id from pubmed: 10.1002/glia.23671-->
<abstract id="ABS1">
<p id="P1">α-Synucleinopathies are neurodegenerative diseases that are characterized pathologically by α-synuclein inclusions in neurons and glia. The pathologic contribution of glial α-synuclein in these diseases is not well understood. Glial α-synuclein may be of particular importance in multiple system atrophy (MSA), which is defined pathologically by glial cytoplasmic α-synuclein inclusions. We have previously described <italic>Drosophila</italic> models of neuronal α-synucleinopathy, which recapitulate key features of the human disorders. We have now expanded our model to express human α-synuclein in glia. We demonstrate that expression of α-synuclein in glia alone results in α-synuclein aggregation, death of dopaminergic neurons, impaired locomotor function, and autonomic dysfunction. Furthermore, co-expression of α-synuclein in both neurons and glia worsens these phenotypes as compared to expression of α-synuclein in neurons alone. We identify unique transcriptomic signatures induced by glial as opposed to neuronal α-synuclein. These results suggest that glial α-synuclein may contribute to the burden of pathology in the α-synucleinopathies through a cell type-specific transcriptional program. This new <italic>Drosophila</italic> model system enables further mechanistic studies dissecting the contribution of glial and neuronal α-synuclein in vivo, potentially shedding light on mechanisms of disease that are especially relevant in MSA but also the α-synucleinopathies more broadly.</p>
</abstract>
<kwd-group>
<kwd>
<italic>Drosophila</italic>
</kwd>
<kwd>glia</kwd>
<kwd>multiple system atrophy</kwd>
<kwd>Parkinson’s disease</kwd>
<kwd>α-Synuclein</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>